- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr. Andrew Seidman Discusses the Management of Patients With Brain Metastases
Over the 20 years I've been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress, said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.
“Over the 20 years I’ve been treating breast cancer, I think this is the one area where we've really lagged behind in terms of making progress,” said Andrew Seidman, MD, attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY.
Dr Seidman says that at the Annual Meeting of the American Society of Clinical Oncologists in Chicago, Aki Morikawa, MD, PhD, Memorial Sloan-Kettering Cancer Center, will present data on two commonly used breast cancer drugs, capecitabine and Lapatinib, to penetrate into breast cancer brain metastases. The observations found in the study should motivate further studies to examine the use of these agents.
This video was taken on May 31, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
